https://orcid.org/0000-0002-6156-5975
Figures & data
Figure 1 Effects of linagliptin on interleukin (IL)-6 induced by lipopolysaccharide (LPS). Human U937 monocytes were treated with LPS and/or linagliptin, and IL-6 levels in the supernatant were evaluated. *p < 0.0001 versus the control; †p < 0.05 versus LPS; ††p < 0.01 versus LPS.
Abbreviation: Lina, linagliptin.
Figure 2 Effects of linagliptin, sitagliptin, and loxoprofen sodium salt dehydrate (Loxo) treatment on LPS-induced IL-6 production. Human U937 monocytes were treated with LPS and/or linagliptin, sitagliptin, or Loxo, and IL-6 levels in the supernatant were evaluated. *p < 0.0001 versus the control; †p < 0.05 versus LPS; ††p < 0.01 versus LPS.
Abbreviations: Lina, linagliptin; Sita, sitagliptin; Loxo, loxoprofen sodium salt dehydrate.
Figure 3 Effects of linagliptin on LPS-induced intranuclear nuclear factor-κB (NF-κB)/p65 levels. Human U937 monocytes were treated with LPS and/or linagliptin, and intranuclear NF-κB/p65 levels were determined. *p < 0.001 versus the control; †p < 0.01 versus LPS.
Abbreviation: Lina, linagliptin.
Figure 4 Effects of linagliptin on intracellular reactive oxygen species (ROS) induced by LPS. Human U937 monocytes were treated with LPS and/or linagliptin, and intracellular ROS levels were determined. *p < 0.05 versus the control; †p < 0.05 versus LPS.
Abbreviation: Lina, linagliptin.
Figure 5 Effects of linagliptin on LPS-binding protein (LBP). Human U937 monocytes were treated with fetal bovine serum (FBS), LPS, and/or linagliptin, and LBP levels in medium were measured.
Abbreviation: Lina, linagliptin.
